Close Menu

NEW YORK – Envisagenics announced Tuesday it has entered into a research program agreement with Johnson & Johnson's Lung Cancer Initiative (LCI.)

Under the terms of the agreement, Envisagenics will build predictive models for lung cancer progression and risk and use its SpliceCore software platform to analyze LCI's data. 

Financial and other details were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.